Belapectin
- Generic Name
- Belapectin
- Drug Type
- Small Molecule
- CAS Number
- 1980787-47-0
- Unique Ingredient Identifier
- K7ODU55HT6
- Background
Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
- Conditions
- Metastatic MelanomaHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Providence Health & Services
- Registration Number
- NCT04987996
- Locations
- 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
- Conditions
- Prevention of Esophageal VaricesCirrhosisNASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 357
- Registration Number
- NCT04365868
- Locations
- 🇺🇸
Impact Research Institute, Waco, Texas, United States
🇨🇱Hospital de La Serena, La Serena, CHL, Chile
🇨🇱ClÃnica Universidad de los Andes, Santiago, CHL, Chile
A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04332432
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
🇺🇸Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
- Conditions
- Non-Small Cell Lung CancerMelanomaSquamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 36
- Registration Number
- NCT02575404
- Locations
- 🇺🇸
Providence Cancer Center, Portland, Oregon, United States
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT02462967
- Locations
- 🇺🇸
University of California Davis Medical Center, Sacramento, California, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
🇺🇸Florida Digestive Health Specialist, Lakewood Ranch, Florida, United States
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02421094
- Locations
- 🇺🇸
Brooke Army Medical Center, Fort Sam Houston, Texas, United States
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02407041
- Locations
- 🇺🇸
Brooke Army Medical Ctr., San Antonio, Texas, United States
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01899859
- Locations
- 🇺🇸
Brooke Army Medical Ctr., San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.